A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea

The purpose of this study is to learn about the safety and effectiveness of Zavicefta once released into the markets in Korea. This study is to learn about Zavicefta in patients with difficult types of infections in the abdomen, urinary tract and pneumonia which could have come from hospitalizations.This study was required by the Ministry of Food and Drug Safety (MFDS) of Korea's regulations.

Adults and paediatric patients aged 3 months and older, who have been administered at least one dose of Zavicefta for the treatment of one of the indications as follows:Complicated intra-abdominal infection (cIAI)Complicated urinary tract infection (cUTI), including pyelonephritisHospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)Other aerobic Gram-negative organism infection with limited treatment optionsAdults 19 years of age or older, who have been administered at least one dose of Zavicefta for the treatment of the indication as follows:•Bacteremia associated with or suspected to be associated with cIAI, cUTI or HAP including VAP.Patients are treated with Zavicefta for the first timePatients have signed the data privacy statement.